GET DAILY SIGNALSCadrenal Therapeutics (CVKD) Set to Report Narrower Q3 2026 Loss
Key Takeaways
- Cadrenal Therapeutics is expected to report third-quarter 2026 results for the period ended September 30, 2026, with consensus estimates pointing to a net loss of $0.91 per share.
- Analysts expect a narrower loss compared with the $1.31 per-share loss reported in the same quarter a year earlier, reflecting a continuing trend of declining quarterly losses.
- As a clinical-stage biopharmaceutical company, Cadrenal is pre-revenue, so investors will focus on operating expenses, cash position, and pipeline progress rather than top-line sales.
- The company beat consensus EPS estimates in its most recent quarter, reporting a loss of $1.14 per share versus the $1.42 consensus forecast.
- Key catalysts to watch include advancing CAD-1005, tecarfarin, and frunexian, alongside the company's capital-efficient partnering strategy.
- For more context on Cadrenal Therapeutics, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
- You can also explore Trending AI Robots to see how automated trading strategies are positioning across the market.
Earnings Context and Why It Matters
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a late-stage biopharmaceutical company advancing therapies for critical care cardiology and orphan cardiovascular conditions. Because the company does not yet generate product revenue, its quarterly earnings releases serve primarily as a window into research and development spending, cash reserves, and clinical progress. For investors, the third-quarter 2026 report matters less for headline earnings and more for what it reveals about the company's ability to fund its pipeline. With a capital-efficient strategy centered on strategic out-licensing and portfolio monetization, the update offers a read on whether Cadrenal can extend its runway while its lead candidates move toward potential partnership or regulatory milestones.
Earnings Expectations
Wall Street's consensus estimate calls for Cadrenal Therapeutics to report a net loss of $0.91 per share for the third quarter of fiscal 2026. The estimate range among three covering analysts spans from a loss of $0.87 to a loss of $0.94 per share. For context, the company reported a loss of $1.31 per share in the year-ago third quarter, so the current consensus implies a meaningful narrowing of the quarterly loss on a year-over-year basis.
Cadrenal has no revenue, so the focus will fall on operating expenses and cash. In its most recent quarter, the company posted a loss of $1.14 per share, beating the $1.42 consensus estimate. Investors will also be watching management's commentary on its recent private placement, which generated approximately $3.0 million in gross proceeds, and on the structured partnering process it has launched for CAD-1005, frunexian, and tecarfarin. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the third-quarter 2026 report, sentiment around Cadrenal Therapeutics reflects a balance between clinical optimism and financing caution. The company has a mixed earnings track record, beating consensus EPS estimates in three of its last eight quarters. Shares have exhibited notable volatility around recent reporting periods, with prior post-earnings moves ranging from single-digit declines to double-digit gains. As a thinly capitalized clinical-stage company, the stock remains sensitive to cash runway concerns and partnership developments. The key risk heading into earnings is that management signals a need for additional capital sooner than expected, which could pressure the share price even if the reported loss comes in narrower than forecast.
Forward Outlook and Key Factors to Monitor
Looking beyond the third-quarter print, investors will want to monitor several closely related themes. First is cash runway. With cash and cash equivalents of roughly $2.4 million reported as of June 30, 2026, and a recent private placement adding approximately $3.0 million in gross proceeds, the company's ability to fund operations into 2027 will be a central question on the earnings call.
Second is the pipeline. Management has positioned CAD-1005 as a differentiated asset across heparin-induced thrombocytopenia (HIT) and cardiac surgery-associated acute kidney injury (CSA-AKI), supported by late-breaking Phase 2 data presented in 2026. Progress in the structured partnering process for CAD-1005, tecarfarin, and frunexian could represent a meaningful non-dilutive catalyst.
Third is regulatory momentum. The company's request for Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease is another potential milestone to track. Finally, investors should watch expense discipline, as narrowing quarterly losses remain the clearest near-term measure of operational execution for this pre-revenue business. From what I see, this is important because it highlights execution in a capital-constrained environment.
How Tickeron AI Tools Support My Analysis
In my own research process, I have found Tickeron's AI Screener useful for quickly filtering clinical-stage biopharma names by fundamentals, technical patterns, and sector trends. It helps surface comparable opportunities and track shifting conditions without manual effort across hundreds of stocks. This kind of tool fits naturally into reviewing pre-revenue companies like CVKD where pipeline and cash metrics matter most.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVKD in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 03, 2026
CVKD broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 27 similar instances where the stock broke above the upper band. In 26 of the 27 cases the stock fell afterwards. This puts the odds of success at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
CVKD moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVKD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CVKD entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CVKD's RSI Indicator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 46 cases where CVKD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on CVKD as a result. In 50 of 65 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +14.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVKD advanced for three days, in 146 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.854) is normal, around the industry mean (3.498). P/E Ratio (-0.201) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CVKD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVKD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement